Race Treatment and Cardiovascular Health: A Study of Men With Prostate Cancer
Abstract
As more men live with their prostate cancer, they face increased risk of cardiovascular disease (CVD); this risk is intensified by treatment type, in particular androgen deprivation therapy (ADT). There is a paucity of data exploring the risk of CVD among minority men with prostate cancer overall or by treatment type. The purpose of this study is to examine race-specific CVD risk in men with prostate cancer, overall and by treatment type. 2000 prostate cancer cases (1000 each African American and Caucasian) were identified and have undergone medical chart review. Pre-diagnosis CVD was common (particularly hypertension). In crude analyses, there is an overall relationship between treatment type (ADT) and post-diagnosis incident CVD (Myocardial infarction [MI]). The majority of these associations were predominantly detected in the Caucasian sample, where ADT was associated with both MI and Type II Diabetes Mellitus. No significant ADT and CVD association was detected in the African-American sample. An unexpected inverse association between ADT and hypertension was detected in crude analyses; further analyses are underway to determine if this is largely due to unaccounted for confounding in the crude analyses. Thus, in our sample, it appears that ADT may have a race-specific association with the development of CVD following prostate cancer treatment. Additional analyses accounting for confounding and other important risk factors are underway.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA580242
Entities
People
- Andrea E. Cassidy-bushrow
Organizations
- Henry Ford Health